These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4085644)

  • 1. [New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].
    de Meglio P; Ravenna F; Manzardo S; Gentili P; Riva M
    Farmaco Sci; 1985 Nov; 40(11):833-44. PubMed ID: 4085644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacological evaluation of a clofibrate-related tricyclic spirolactone, 5-chloro-4',5-dihydrospiro[benzofuran-2(3H),3'(2'H)-furan]-2'-one.
    Witiak DT; Cavestri RC; Newman HA; Baldwin JR; Sober CL; Feller DR
    J Med Chem; 1978 Dec; 21(12):1198-202. PubMed ID: 722728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of probucol on triton induced hyperlipidemias in CFY rats.
    Krishnamurthy A; Thapar GS; Shridhar DR
    Artery; 1985; 13(2):87-94. PubMed ID: 4084069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer hypolipidemic compounds.
    Kritchevsky D
    Adv Exp Med Biol; 1975; 63():135-50. PubMed ID: 1106139
    [No Abstract]   [Full Text] [Related]  

  • 6. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.
    Davignon J
    Am J Cardiol; 1998 Apr; 81(8A):17F-24F. PubMed ID: 9604899
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacology of probucol. I].
    Donatelli L
    Clin Ter; 1984 Mar; 108(5):367-88. PubMed ID: 6232074
    [No Abstract]   [Full Text] [Related]  

  • 9. Syntheses and biological evaluation of 3-substituted amino-1-aryl-6-hydroxy-hex-2-ene-1-ones as antioxidant and hypolipidemic agents.
    Batra S; Srivastava S; Singh K; Chander R; Khanna AK; Bhaduri AP
    Bioorg Med Chem; 2000 Aug; 8(8):2195-209. PubMed ID: 11003164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypolipidaemic aryloxyacetic acids.
    Schacht E
    Top Curr Chem; 1977; 72():99-123. PubMed ID: 339406
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antilipidemic effects of various ethyl 5-substituted benzofuran-, 2,3-dihydrobenzofuran-, and 3(2H)-benzofuranone-2-carboxylate analogs of clofibrate in a triton hyperlipidemic rat model.
    Witiak DT; Newman HA; Poochikian GK; Loh W; Sankarappa SK
    Lipids; 1976 May; 11(5):384-91. PubMed ID: 1271976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
    Barnard SD; Molello JA; Caldwell WJ; LeBeau JE
    J Toxicol Environ Health; 1980 May; 6(3):547-57. PubMed ID: 7420463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanisms of action of etophylline-clofibrate in hyperlipidemia].
    Păduraru I; Nechifor M; Dănilă G; Jercă L; Filip M; Iacobovici A; Teslaru E; Filip C; Saramet A
    Rev Med Chir Soc Med Nat Iasi; 1993; 97(1):445-9. PubMed ID: 8153471
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypolipidaemic agents (author's transl)].
    Tillement JP; Albengres E; Choisy H; Millart H
    Nouv Presse Med; 1980 Oct; 9(40):2947-50. PubMed ID: 7443428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 Jun; 15(6):409-28. PubMed ID: 350557
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and antilipidemic properties of cis-7-chloro-3a, 8b-dihydro-3a-methylfuro[3,4-b]benzofuran-3(1H)-one, a tricyclic clofibrate related lactone having a structural resemblance to mevalonolactone.
    Witiak DT; Kuwano E; Feller DR; Baldwin JR; Newman HA; Sankrappa SK
    J Med Chem; 1976 Oct; 19(10):1214-20. PubMed ID: 994152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive effects of clofibrate and probucol (DH-581) on rat serum cholesterol.
    Duncan CH; Best MM
    Atherosclerosis; 1973; 17(2):161-6. PubMed ID: 4709117
    [No Abstract]   [Full Text] [Related]  

  • 20. Probucol-lipid pharmacology.
    Kritchevsky D
    Artery; 1982; 10(1):1-6. PubMed ID: 6807261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.